Assessment of Fluoroquinolone and Aminoglycoside Resistance Using Line Probe Assay in Multidrug-Resistant Tuberculosis Patients
Keywords:
Multidrug-Resistant Tuberculosis, Fluoroquinolone Resistance, Aminoglycoside Resistance, Line Probe Assay, Drug Resistance, Mycobacterium Tuberculosis.Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) is a severe public health issue, especially if resistance to fluoroquinolones (FQs) and aminoglycosides (AGs) limits therapeutic choices.
Objective: To assess the prevalence of FQ and AG resistance and the corresponding resistance mutations among MDR-TB patients by line probe assay (LPA).
Methods: This descriptive cross-sectional study was done in the TB diagnostic laboratory of a tertiary care hospital in Pakistan during six months from February to July 2026. Patients with confirmed MDR-TB were consecutively sampled, and 100 patients were enrolled. Specimens were tested using the GenoType MTBDRsl VER 2.0 LPA (Hain Lifescience, Nehren, Germany), which is able to detect mutations in gyrA and gyrB (FQ resistance) and in rrs and the eis promoter (AG resistance). Descriptive analysis and 95% Wilson confidence intervals for proportions were used to analyse data. No phenotypic drug susceptibility testing was done.
Results: FQ resistance was detected in 38% of patients (95% CI 29.1–47.8) and AG resistance in 24% (95% CI 16.7–33.2). 47% had at least one drug class resistance, and 15% had both drug classes resistance. Mutations in gyrA were responsible for 81.6% (31/38) of FQ-resistant cases, and mutations in rrs for 75.0% (18/24) of AG-resistant cases. The 38 patients who were found to be resistant to FQ were classified as pre-extensively drug-resistant TB (pre-XDR-TB) according to the WHO definitions; susceptibility to bedaquiline and linezolid was not tested and could not be used to classify as extensively drug-resistant TB (XDR-TB).
Conclusion: MDR-TB cases had second-line drug resistance rates. LPA can quickly identify resistance-associated mutations and assist in providing timely, individual treatment decisions, preferably with phenotypic confirmation.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Authors

This work is licensed under a Creative Commons Attribution 4.0 International License.



